Net sales of diabetes medicines of Novo Nordisk in Greater China 2022, by product
In 2022, the Danish pharmaceutical company Novo Nordisk reported that its long-acting insulin medication Levemir® had generated about 0.54 billion Danish kroner in Greater China. After two years of launching its another long-acting insulin product Tresiba® in China, the firm had recorded a significant sales growth of the medication in 2021.